Vimarsana
Biggest News Aggregation in the World

Page 43 - Aduhelm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aduhelm Today - Breaking & Trending Today

Sanders to Biden: Cut back looming Medicare premium hike - Vimarsana News

Sanders to Biden: Cut back looming Medicare premium hike

WASHINGTON (AP) — Sen. Bernie Sanders is asking the White House to cut back a big...

Bernie Sanders Asks Biden to Prevent Medicare Premium Hike Tied to Pricey Alzheimer's Drug - Vimarsana News

Bernie Sanders Asks Biden to Prevent Medicare Premium Hike Tied to Pricey Alzheimer's Drug

The premium increase is so Medicare will have a reserve prepared if the program formally grants coverage for the drug Aduhelm, Medicare said.

Sanders urges Biden to delay Medicare prmium hike linked to Alzheimer's drug - Vimarsana News

Sanders urges Biden to delay Medicare prmium hike linked to Alzheimer's drug

Sen. Bernie Sanders (I-Vt.) is calling on the Biden administration to delay an increase in Medicare premiums for 2022 that is tied in part to a controversial, pricey Alzheimer's drug.

'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement - Vimarsana News

'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement

Fierce Biotech profiles three women breaking barriers in Alzheimer's disease R&D at leading pharmaceutical companies. Today, Eli Lilly's donanemab launch leader Brandy Matthews.

Hopes and concerns over a new Alzheimer's drug - Vimarsana News

Hopes and concerns over a new Alzheimer's drug

The FDA's recent approval of a new drug, Aduhelm, to clear the formation of amyloid plaques in the brain is potentially good news for the six million Americans who suffer from Alzheimer's disease. But the drug's approval process has stirred controversy.